Nature Medicine, Published online: 31 March 2026; doi:10.1038/s41591-026-04315-8

Benralizumab (an anti-IL-5 receptor α antibody), compared to placebo, significantly reduced the risk of first flare in patients with hypereosinophilic syndrome.

Nature Medicine, Published online: 25 March 2026; doi:10.1038/s41591-026-04299-5

Results of the phase 2 POLAR trial show that biomarker-guided treatment in patients with metastatic pancreatic cancer based on homologous repair deficiency leads to encouraging clinical response rates in immune cell-infiltrated tumors.

Nature Medicine, Published online: 24 March 2026; doi:10.1038/s41591-026-04262-4

The first-in-human clinical trial of the LRRK2-targeting antisense oligonucleotide BIIB094 in Parkinson’s disease demonstrates that the treatment is well tolerated and produces dose-dependent reductions in cerebrospinal fluid levels of LRRK2 and phosphorylated Rab10, indicating successful target engagement.

Nature Medicine, Published online: 16 March 2026; doi:10.1038/s41591-026-04306-9

In cohort 4 of the ILUSTRO trial, combination of anti-CLDN18.2 zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18.2-positive, HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma led to encouraging clinical efficacy, supporting the testing of this combination in a phase 3 trial.

Nature Medicine, Published online: 12 March 2026; doi:10.1038/s41591-026-04265-1

In this phase 1, open-label dose-escalation study in healthy adults found that the mRNA vaccine (mRNA-1215), encoding the Nipah virus Malaysian strain chimeric pre-fusion F protein linked to glycoprotein G, was safe and induced elevated immune responses at 1 year of follow-up, indicating that this is a promising vaccine candidate for further development.

Nature Medicine, Published online: 12 March 2026; doi:10.1038/s41591-026-04278-w

A real-world study showed that introducing a cognitive layer architecture to support specialized psychotherapeutic reasoning capabilities in general-purpose chatbots improved depression and anxiety symptoms compared to chatbots or therapists alone.

Nature Medicine, Published online: 11 March 2026; doi:10.1038/s41591-026-04272-2

Elevated serum levels of phosphorylated tau are not specific to Alzheimer’s disease and may also serve as a diagnostic tool for the most common types of systemic amyloidosis, with potential utility in distinguishing amyloidosis-related polyneuropathy from polyneuropathy of other etiologies.